预约演示
更新于：2025-06-21
Imexon
更新于：2025-06-21
概要
基本信息
原研机构 |
在研机构- |
非在研机构 |
权益机构- |
最高研发阶段终止临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C4H5N3O |
InChIKeyBIXBBIPTYBJTRY-UHFFFAOYSA-N |
CAS号59643-91-3 |
关联
8
项与 Imexon 相关的临床试验NCT01314014
A Phase II Study of Amplimexon® (Imexon for Injection) for the Treatment of Previously Treated Follicular and Aggressive Lymphoma in Adults
NCT00697060
A Multicenter, Phase II Trial of the Safety and Efficacy of Amplimexon® (Imexon for Injection) in Combination With Taxotere® (Docetaxel) for Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT00637247
A Phase 2 Randomized, Double-Blind, Multicenter Trial of Amplimexon® Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy Naïve Pancreatic Adenocarcinoma (Stage IV)
100 项与 Imexon 相关的临床结果
登录后查看更多信息
100 项与 Imexon 相关的转化医学
登录后查看更多信息
100 项与 Imexon 相关的专利（医药）
登录后查看更多信息
110
项与 Imexon 相关的文献（医药）2024-11-01Translational Oncology
Disulfidptosis-related gene expression reflects the prognosis of drug-resistant cancer patients and inhibition of MYH9 reverses sorafenib resistance
Article
作者: Zhang, Kangnan ; Zhou, Jingyi ; Zhu, Zhenhua ; Wang, Na ; Xu, Ling ; Yu, Fudong ; Shi, Min
The onset of drug resistance in advanced cancer patients markedly diminishes their prognosis. Recently, disulfidptosis, a novel form of cell death, has been identified, triggered by excessive disulfide formation leading to cell shrinkage and F-actin contraction. Previous studies have identified 15 essential genes (FLNA, FLNB, MYH9, TLN1, ACTB, MYL6, MYH10, CAPZB, DSTN, IQGAP1, ACTN4, PDLIM1, CD2AP, INF2, SLC7A11) associated with disulfidptosis. This study sourced pan-cancer mRNA expression data from Xena to thoroughly evaluate the molecular and clinical characteristics of disulfidptosis-related genes. Through unsupervised clustering, mRNA expression data identified the expression levels of disulfidptosis-related genes and potential clusters related to this form of cell death. Kaplan-Meier survival curves illustrated the correlation between different clusters and overall survival. The findings reveal that high expression of disulfidptosis-related genes is linked to poor survival in liver cancer. The GDSC database was utilized to analyze the relationship between disulfidptosis-related genes and the AUC of 198 drugs. The results demonstrate that 12 disulfidptosis-related genes influence sorafenib resistance, as revealed by the intersection of differential genes related to sorafenib resistance from the GSE109211 dataset. Among them, the MYH9 gene was found to play a crucial role in both. Finally, experimental evidence confirmed that MYH9 mitigates sorafenib resistance in hepatocellular carcinoma through disulfidptosis-like changes. This study identifies disulfidptosis as a promising avenue for enhancing the sensitivity of tumor cells to drugs, offering new therapeutic perspectives for future research on disulfidptosis and drug resistance in cancer patients.
2024-08-01CELL BIOLOGY INTERNATIONAL
Single‐cell and bulk RNA‐sequencing reveals mitosis‐involved gene HAUS1 is a promising indicator for predicting prognosis and immune responses in prostate adenocarcinoma (PRAD)
Article
作者: Yu, Yang ; Xu, Jie ; Li, Deng ; Wang, Yi ; Liu, Shiwei
Abstract:
It was imperative to identify latent biomarkers pertinent to malignancies, given the pivotal role targeted molecular therapies play in tumor treatment investigations. This study aimed to assess the validity of HAUS1 as an indicator for survival prognosis and immune responses in prostate adenocarcinoma (PRAD) via single‐cell and bulk RNA‐sequencing. Related data on HAUS1 expression in PRAD were obtained from online databases, followed by comprehensive analyses to delineate its associations with survival prognosis, implicated pathways, and immune responses. Besides, the expression pattern of HAUS1 in PRAD was also verified in vitro, by using qRT‐PCR, Western blot analysis, and immunohistochemistry. We found HAUS1 was downregulated in PRAD compared with normal tissues, as verified in vitro by qRT‐PCR, Western blot, and immunohistochemistry (p < 0.05). Single‐cell RNA‐sequencing analysis indicated that HAUS1 had relatively higher expressions in B cells, Mono/Macro cells, and Endothelial cells compared with other cell types. Cox regression analysis revealed HAUS1 could serve as an independent indicator for the overall survival prognosis of PRAD (p < 0.05). Spearman correlation analyses revealed HAUS1 was closely related to the tumor microenvironment, immune cell infiltration levels, immune checkpoints, and immune cell pathways (p < 0.05). Furthermore, HAUS1 expression was found to be closely related to the immunotherapeutic response of patients receiving clinical intervention (p < 0.05). Collectively, our findings underscored the significant role of HAUS1 in PRAD prognosis and immune response, thereby presenting a novel and promising avenue for investigating the clinical utility of immunotherapy in PRAD.
2023-05-01JOURNAL OF MOLECULAR LIQUIDS
Adsorption of 40 low molecular weight drugs on pristine and fluorinated C60 fullerenes: Ab initio, statistical and neural networks analysis
作者: Kochaev, Alexey I. ; Grekova, Anastasiya A. ; Maslov, Mikhail M. ; Katin, Konstantin P. ; Bondarev, Nikolay V. ; Kaya, Savas ; Bauetdinov, Yusupbek A. ; Kalika, Elizaveta B.
Loading of 40 small drugs mols. with mol. weights in 47-210 g/mol range consisted of H, C, N, O, F, S elements on C60, C60F2 and C60F48 fullerenes are studied with the d. functional theory.Adsorption energies as well as deformation energies of fullerenes and drugs are calculatedThe C60F2 is recognized as the most active drugs adsorbent.Mean adsorption energies averaged over all considered drugs are 0.41, 0.59 and 0.54 eV with standard deviations of 0.10, 0.09 and 0.14 eV for C60, C60F2 and C60F48 fullerenes, resp.Mean energies of drug-induced deformations of C60, C60F2 and C60F48 are 8.6, 12.0 and 16.6 meV, resp.Multilinear regressions and neural networks were proposed for prediction of adsorption energies based on dipole moments and frontier MOs of the drugs.Achievable accuracy of such predictions is about 0.1 eV.Altretamine antibiotic is recognized as the notable drug possessing extremely high binding energies about 1 eV with fullerenes.IR spectral shifts due to its loading on fullerene carriers are calculated
100 项与 Imexon 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 转移性非小细胞肺癌 | 临床2期 | 美国 | 2010-08-01 | |
| 转移性胰腺腺癌 | 临床2期 | 美国 | 2008-04-01 | |
| 多发性骨髓瘤 | 临床2期 | 美国 | 2005-10-01 | |
| 不可切除的黑色素瘤 | 临床2期 | 美国 | 2005-07-01 | |
| 乳腺癌 | 临床1期 | 美国 | 2005-10-01 | |
| 去势抵抗性前列腺癌 | 临床1期 | 美国 | 2005-10-01 | |
| 晚期胰腺腺癌 | 临床1期 | 美国 | 2004-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | B细胞淋巴瘤 CD68 | GPX1 | SOD2 | - | Imexon 1000 mg/m(2) | 壓鹹膚遞繭製獵襯鬱糧(鹹糧選鹹膚構蓋夢壓齋) = 憲獵遞繭繭製餘鹽鏇餘 憲窪衊鬱獵繭艱網積鬱 (衊願壓糧夢遞窪遞繭積 ) | - | 2014-08-21 | |
临床2期 | 22 | 獵蓋願網鹹觸獵齋製蓋 = 窪獵餘糧鬱網簾鑰艱獵 鹹窪獵觸壓淵鹽衊糧壓 (獵鬱獵壓選鑰顧淵艱憲, 構築廠積顧糧獵艱餘衊 ~ 鬱餘獵繭獵壓餘製淵鹽) 更多 | - | 2014-07-01 | |||
临床2期 | 142 | (Imexon + Gemcitabine) | 夢憲糧製淵積膚範糧繭 = 簾簾願鹹獵醖獵窪餘壓 鑰構餘淵獵獵築鏇窪蓋 (齋鏇鹽襯鹹繭膚觸觸顧, 觸淵製衊獵淵夢顧積鑰 ~ 築衊願願築製窪淵廠鏇) | - | 2010-11-30 | ||
imexon placebo + gemcitabine (Placebo + Gemcitabine) | 夢憲糧製淵積膚範糧繭 = 簾築鹹壓選鏇鬱簾壓製 鑰構餘淵獵獵築鏇窪蓋 (齋鏇鹽襯鹹繭膚觸觸顧, 願蓋壓齋鏇獵繭觸鬱糧 ~ 鏇夢選構壓憲簾齋醖蓋) | ||||||
临床1期 | 34 | 鑰製獵觸齋艱壓壓淵積(顧夢積膚醖鬱網齋積醖) = 構齋鑰網鑰鏇夢廠淵觸 顧繭餘餘顧製鏇膚積願 (夢鏇襯觸簾膚壓齋艱簾 ) | - | 2010-10-01 | |||
临床1/2期 | 68 | 簾鹽夢簾膚餘選選襯夢(構襯簾艱夢壓夢窪襯鏇) = 窪網齋憲憲繭淵艱網觸 願醖壓齋簾憲觸廠築構 (餘廠鬱顧蓋衊憲壓積構 ) 更多 | - | 2010-08-01 | |||
临床1期 | 胰腺癌 一线 | 105 | 選壓範遞艱鬱觸鏇製壓(襯鏇遞襯鏇鏇鬱願餘蓋) = 餘餘夢衊鏇壓繭鬱選夢 衊憲窪窪壓遞積齋壓餘 (獵簾窪築夢憲壓淵構鹹 ) | - | 2010-07-01 | ||
临床1/2期 | 68 | 積鑰膚簾蓋蓋獵鏇衊廠(醖蓋鑰鬱積顧艱窪鹽壓) = Seven Pts had SAEs that were possibly or definitely related to treatment 壓襯鬱選襯憲艱餘蓋艱 (淵顧艱壓膚觸膚網餘顧 ) 更多 | - | 2008-05-20 | |||
临床1期 | 29 | 選廠範鹹願糧醖齋淵齋(簾選獵遞夢繭齋積廠鏇) = transient, grade 3–4 non cardiac chest pain (w/o enzyme elevations or EKG changes) in 3/3 pts with pulmonary metastases 製顧選鏇築膚窪顧糧餘 (構築齋襯糧顧範襯餘繭 ) 更多 | - | 2008-05-20 | |||
临床1期 | 30 | 積繭範範觸廠積遞憲製(糧膚醖鹽鏇構壓窪鬱齋) = 蓋鏇簾網遞範淵膚獵蓋 範網構夢積膚鑰鏇遞壓 (淵膚製夢壓顧夢製繭齋 ) | - | 2005-06-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用